CD274 and non-small cell lung carcinoma: 2.6. Add-On Abnobaviscum® Therapy Is Associated with Reduced Hazard of Death in PD-L1 Positive (≥1%) NSCLC Patients Treated with First-Line PD-1 Inhibitors